News | Radiopharmaceuticals and Tracers | February 07, 2017

Blue Earth Diagnostics and Siemens' PETNET Solutions Increase Patient Access to Axumin Injection PET Imaging Agent

Agent for imaging of recurrent prostate cancer will be added to several sites in PETNET’s nationwide network throughout 2017

Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access

February 7, 2017 — Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will offer Blue Earth Diagnostics’ Axumin (fluciclovine F-18) positron emission tomography (PET) imaging agent through PETNET’s national network.

In June 2016, PETNET Solutions began exclusive commercial production and distribution of Axumin at two sites in the United States, and additional sites have been rolled out in subsequent months. There are now 12 metropolitan locations in the United States offering Axumin, including the recent addition of sites in Phoenix, Ariz., and Ft. Lauderdale, Fla., with more sites planned during 2017. Axumin is a novel molecular imaging agent indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men who have elevated blood levels of prostate specific antigen (PSA) following prior treatment. It is the first U.S. Food and Drug Administration (FDA)-approved F-18 PET imaging agent indicated for use in patients with suspected recurrent prostate cancer.

Blue Earth Diagnostics CEO Jonathan Allis, D.Phil, announced that Axumin reader training is available in collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), including a recent live training event at SNMMI’s Mid-Winter Meeting.

According to Allis, the Centers for Medicare and Medicaid Services (CMS) has granted Axumin transitional pass-through payment reimbursement status using a product-specific Healthcare Common Procedure Coding System (HCPCS) A code (A9588), which became effective Jan. 1 of this year.

Prostate cancer is the second leading cause of cancer death in men. While most primary prostate cancer can be successfully treated, recurrence occurs in up to one-third of patients. Recurrent disease is typically detected by a rise in PSA levels, but often the location and extent of the disease cannot be detected by conventional imaging. Of those patients who experience biochemical recurrence, approximately one-third go on to develop metastatic prostate cancer.

For more information: www.blueearthdiagnostics.com, www.usa.healthcare.siemens.com/molecular-imaging/petnet-solutions

Related Content

Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Prostate Radiotherapy Outcomes Better for African-Americans Than Caucasian Patients according to a study presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
Feature | Prostate Cancer | October 30, 2018
October 30, 2018 — While popular beliefs and population data suggest that African-American men are at higher risk of
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Combined Therapy Including Pelvic Lymph Node Radiation Provides Significant Benefit for Prostate Cancer Patients - late breaking study presented at ASTRO 2018.
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...